Anacor Pharmaceuticals Announces Presentations at the American Academy of Dermatology Annual Meeting

PALO ALTO, Calif.--()--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that the following abstracts have been accepted for presentation at the upcoming 73rd Annual Meeting of the American Academy of Dermatology to be held in San Francisco, California March 20 to 24, 2015:

  • AN2728, an investigational non-steroidal topical PDE-4 inhibitor for the potential treatment of mild-to-moderate atopic dermatitis in children and adults
    • "Maximal Use Systemic Exposure (MUSE) Study Evaluating AN2728, A Novel Boron-Based Small Molecule, for the Treatment of Pediatric and Adolescent Subjects with Mild-to-Moderate Atopic Dermatitis” to be presented by Zoe Draelos, M.D. on Friday, March 20 at 4:30 P.D.T.
    • “AN2728, A New Boron-Based Topical Anti-Inflammatory Agent, Inhibits Phosphodiesterase 4” to be presented by Lee Zane, M.D. on Saturday, March 21 at 9:25 a.m. P.D.T.
  • KERYDIN (tavaborole) topical solution, 5%
    • “In Vitro Study Demonstrating Nail Penetration of Tavaborole Topical Solution, 5% Through Multiple Layers of Nail Polish” to be presented by Tracey Vlahovic, DPM, on Sunday, March 22 at 11:35 a.m. P.D.T.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s first approved drug, KERYDIN® (tavaborole) topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the topical treatment of onychomycosis of the toenails. In July 2014, Anacor entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN in the United States. In September 2014, PharmaDerm launched KERYDIN in the United States. Anacor’s lead product candidate is AN2728, an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. Beyond KERYDIN and AN2728, Anacor has discovered three investigational compounds that it has out-licensed for further development. The first compound is licensed to Eli Lilly and Company for the potential treatment of an animal health indication. The second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative for the potential treatment of human African trypanosomiasis (HAT, or sleeping sickness). The third compound is licensed to GlaxoSmithKline LLC for development in tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development. These include AN3365, an investigational Gram-negative antibiotic, and certain other wholly-owned investigational product candidates. For more information, visit http://www.anacor.com.

Contacts

Anacor Pharmaceuticals, Inc.
DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications

Contacts

Anacor Pharmaceuticals, Inc.
DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications